Compounds of formula I:
(wherein variables A
1
, A
2
, A
3
, A
4
, A
5
, A
6
, A
7
, B, E
1
, E
2
, E
3
, E
4
, E
5
, G
1
, G
2
and R
6
are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Imidazopyridines and imidazopyrazines as LSD1 inhibitors
申请人:Incyte Corporation
公开号:US10640503B2
公开(公告)日:2020-05-05
The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
本发明涉及式 I 的咪唑并[1,5-a]吡啶和咪唑并[1,5-a]吡嗪衍生物或其药学上可接受的盐,它们是治疗癌症等疾病的 LSD1 抑制剂。